Benjamin Halladay
Director Financiero/CFO en ESPERION THERAPEUTICS, INC. .
Fortuna: 526 902 $ al 31/05/2024
Perfil
Benjamin Halladay is currently the Chief Financial Officer at Esperion Therapeutics, Inc. He previously worked as the Global Finance Manager at NOV, Inc. from 2016 to 2017.
Mr. Halladay completed his undergraduate degree at Syracuse University and holds an MBA from Fordham Gabelli School of Business.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 14/03/2024 | 243 936 ( 0.14% ) | 526 902 $ | 31/05/2024 |
Cargos activos de Benjamin Halladay
| Empresas | Cargo | Inicio |
|---|---|---|
| ESPERION THERAPEUTICS, INC. | Director Financiero/CFO | 16/11/2022 |
Antiguos cargos conocidos de Benjamin Halladay.
| Empresas | Cargo | Fin |
|---|---|---|
| NOV INC. | Corporate Officer/Principal | 01/05/2017 |
Formación de Benjamin Halladay.
| Syracuse University | Undergraduate Degree |
| Fordham Gabelli School of Business | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ESPERION THERAPEUTICS, INC. | Health Technology |
| NOV INC. | Industrial Services |
- Bolsa de valores
- Insiders
- Benjamin Halladay
